• scottlissington

New Antibiotic registered to treat Urinary Tract Infections (UTI)

Updated: May 25

MacroBID® is a new antibiotic medicine Medsafe registered by Te Arai BioFarma.

MacroBID® is a modified release nitrofurantoin containing nitrofurantoin macrocrystals and nitrofurantoin monohydrate for the treatment of acute, symptomatic, uncomplicated UTIs.

MacroBID® allows convenient twice daily dosing.

MacroBID® will be fully funded by PHARMAC from 1 March 2021 following a high priority recommendation based on improved compliance, reduced side effects and a lower risk of resistance.

"Antibiotic stewardship is extremely important for all societies across the world. For this reason, it was viewed as important to make available a twice daily formulation of nitrofurantoin which is recommended as first line treatment for acute UTIs. Through a long-term collaboration with an important international partner, Te Arai BioFarma has successfully made MacroBID® available to New Zealand patients." Scott Lissington COO, Te Arai BioFarma.

For more information please contact:


Te Arai BioFarma Ltd 0800 TE ARAI

MacroBID® is a Prescription Medicine. For full information please consult the Medsafe website and product data sheet at MacroBID® is a registered Trademark of the Alvogen Group of companies.

Te Arai BioFarma is a New Zealand owned family company created to improve access to Medicines for New Zealanders.

41 views0 comments

Recent Posts

See All

MacroBID Dear Healthcare Professional Letter

Please find the "Dear Healthcare Professional Letter" containing additional information about the release characteristics and in-use shelf life of Macrobid® (nitrofurantoin macrocrystals/nitrofurantoi